[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345670-105":59,"doc-detail-345670-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","small-molecule-liver-x-receptor-modulator-gac0001e5-targets-mechanisms-of-endocrine-resistance-in-estrogen-receptor-positive-breast-cancer-cells","Small Molecule Liver X Receptor Modulator - GAC0001E5 Targets Mechanisms of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer Cells","","Endocrine therapy is an effective and common treatment strategy for estrogen receptor (ER)-positive breast cancers. However, endocrine resistance develops in about 40% of treated patients through genetic mutations and epigenetic alterations, creating a major therapeutic challenge. Liver X receptors (LXRs) regulate lipid metabolism and cholesterol homeostasis and have been linked to metabolic reprogramming in breast cancers. This study dissects how the novel LXR ligand GAC0001E5 (1E5) acts in responsive (MCF-7) and endocrine-resistant (MCF-7-TamR) ER-positive cells, showing downregulation of LXR, targets, ERα and ER-responsive genes, with partial effects from LXR siRNA suggesting both LXR-dependent and independent mechanisms.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/small-molecule-liver-x-receptor-modulator-gac0001e5-targets-mechanisms-of-endocrine-resistance-in-estrogen-receptor-positive-breast-cancer-cells/345670/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/small-molecule-liver-x-receptor-modulator-gac0001e5-targets-mechanisms-of-endocrine-resistance-in-estrogen-receptor-positive-breast-cancer-cells/345670.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is endocrine resistance a significant challenge in ER-positive breast cancer?","Question",{"text":112,"@type":113},"Endocrine resistance limits the long-term effectiveness of therapies and leads to disease recurrence. It arises in a substantial proportion of patients through genetic mutations and epigenetic alterations.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is GAC0001E5 (1E5) and what is it being studied for?",{"text":117,"@type":113},"GAC0001E5 (1E5) is a small-molecule LXR inverse agonist and degrader. The article investigates its mechanisms of action in tamoxifen-sensitive and tamoxifen-resistant ER-positive breast cancer cells.",{"name":119,"@type":110,"acceptedAnswer":120},"How does 1E5 affect LXR signaling and ER-related gene expression?",{"text":121,"@type":113},"Treatment with 1E5 downregulates LXR and its target genes, and it significantly reduces ERα expression and ER-responsive gene expression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345670,1790873647,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Article  \nSmall Molecule Liver X Receptor Modulator GAC0001E5 Targets Mechanisms of Endocrine Resistance in Estrogen  \nReceptor-Positive Breast Cancer Cells  \nShinjini Basu 1, Asitha Premaratne 1, Scott Widmann 2,3, Esther A. Olaleye 2,3 and Chin-Yo Lin 1, *  \n1 Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX 77004, USA  \n2 Center for Biomedical and Health Research, Texas Southern University, Houston, TX 77004, USA  \n3 Biomolecular Research and Advanced Computing Center, Texas Southern University, Houston, TX 77004, USA  \n* Correspondence: [clin23@central.uh.edu](clin23@central.uh.edu)  \nAcademic Editor: Fabian Benencia  \nReceived: 30 April 2026  \nRevised: 28 May 2026  \nAccepted: 6 June 2026  \nPublished: 11 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nAbstract  \nEndocrine therapy is an effective and common treatment strategy for estrogen receptor (ER)-positive breast cancers. However, the development of endocrine resistance, through genetic mutations and epigenetic alterations, in about 40% of treated patients remains a significant therapeutic challenge. Liver X receptors (LXRs) are nuclear receptors that regulate lipid metabolism and cholesterol homeostasis and have been implicated in metabolic reprogramming in breast cancers and other malignancies. We previously identified a novel LXR ligand GAC0001E5 (1E5), with potent antiproliferative activity across breast cancer subtypes. Here, we investigate its mechanisms of action in responsive (MCF-7) and endocrine-resistant (MCF-7-TamR) ER-positive breast cancer cells. Treatment with 1E5 resulted in the downregulation of LXR and its target genes, and significantly reduced ERα expression and the expression of ER-responsive genes. Aberrant expression of androgen receptor (AR) and human epidermal growth factor receptor 2 (HER2), both implicated in endocrine resistance, were downregulated following 1E5 treatment. siRNA-mediated knockdown of LXR expression only partially recapitulated the actions of 1E5, suggesting the involvement of LXR-dependent and independent mechanisms. Collectively, these findings reveal potential crosstalk between LXR and the genetic and epigenetic regulation of pathways involved in endocrine response and alternative signaling mechanisms, highlighting potential targets in endocrine-resistant breast cancer.  \nKeywords: breast cancer; liver X receptor; estrogen receptor; endocrine resistance  \n1. Introduction  \nBreast cancer is one of the leading causes of cancer-related mortality among women worldwide [1] . Although advances in screening and endocrine therapies have greatly improved patient outcomes, endocrine resistance remains a major clinical challenge, necessitating further investigation into resistant mechanisms and alternative therapeutic approaches.  \nHormone receptor-positive breast cancer accounts for approximately 70% of all breast cancer cases [2] . Estrogen receptor α (ERα) serves as the primary oncogenic driver by promoting aberrant cell proliferation and survival. Endocrine therapies targeting ER signaling, including selective estrogen receptor modulators (SERMs), aromatase inhibitors, and selective estrogen receptor degraders (SERDs), have long represented the standard of care for  \nthis subtype, with considerable success [3] . However, accumulating evidence indicates that genetic and epigenetic alterations contribute to endocrine resistance and disease recurrence in a significant subset of patients [4,5] . Mutations in the ERα ligand-binding domain, gene rearrangements or fusions, ERα amplification, and epigenetic reprogramming have all been linked to endocrine resistance [6] . Additional compensatory mechanisms, including aberrant expression of androgen receptor (AR) and human epidermal growth factor re","cbCaigDNuZA81THg","https://ap.wps.com/l/cbCaigDNuZA81THg","pdf",10528587,"English","# Introduction\n# Materials and Methods\n## Cell Culture and Treatments","[{\"question\":\"Why is endocrine resistance a significant challenge in ER-positive breast cancer?\",\"answer\":\"Endocrine resistance limits the long-term effectiveness of therapies and leads to disease recurrence. It arises in a substantial proportion of patients through genetic mutations and epigenetic alterations.\"},{\"question\":\"What is GAC0001E5 (1E5) and what is it being studied for?\",\"answer\":\"GAC0001E5 (1E5) is a small-molecule LXR inverse agonist and degrader. The article investigates its mechanisms of action in tamoxifen-sensitive and tamoxifen-resistant ER-positive breast cancer cells.\"},{\"question\":\"How does 1E5 affect LXR signaling and ER-related gene expression?\",\"answer\":\"Treatment with 1E5 downregulates LXR and its target genes, and it significantly reduces ERα expression and ER-responsive gene expression.\"}]","Small Molecule Liver X Receptor Modulator - GAC0001E5 Targets Mechanisms of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer Cells | PDF",1790058532,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c3559119d4ef22c6d243d4cc964a998.webp",983,1390,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff105073723e29d47b15e908babea523.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/06059a173dcb5a45b6ff19f799cb376d.webp",981,1387,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7931ff4e91a639f0f5b4f45573d19b4.webp",980,1385]